A New Milestone in Ophthalmology The landscape for treating serious eye conditions has expanded. The U.S. Food and Drug Administration (FDA) has officially approved Lucamzi (ranibizumab-blrz), a biosimilar to the well-known reference product, Lucentis. This approval marks an important step in providing healthcare providers and patients with additional treatment alternatives for managing vision-related diseases. What…